MTOR and idiopathic pulmonary fibrosis: Omipalisib, a PI3K/mTOR inhibitor, has been used in a clinical trial study of IPF, and the results indicated that PI3K-targeted engagement had a demonstrable effect on lung metabolism in fibrotic lung.